TSE:GUD

Knight Therapeutics (GUD) Stock Forecast, Price & News

C$4.98

+0.03 (+0.61%)

(As of 06/9/2023 ET)

Compare

Today's Range: C$4.95
▼
C$4.98
50-Day Range: C$4.42
▼
C$4.98
52-Week Range: C$4.28
▼
C$6.20

Volume: 84,921 shs
Average Volume: 123,292 shs
Market Capitalization: C$542.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: C$5.97

Profile Analyst Ratings Chart Competitors Earnings Insider Trades Headlines Social Media

About Knight Therapeutics (TSE:GUD) Stock

Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.

Receive GUD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GUD Stock News Headlines

June 7, 2023 | theglobeandmail.com

Closing Bell: Knight Therapeutics Inc up on Tuesday (GUD)

June 2, 2023 | finance.yahoo.com

Knight to Present at the Jefferies 2023 Healthcare Conference in New York City

June 10, 2023 | Legacy Research (Affiliate) (Ad)

“One-Stock Millionaire” IGNORES 99.9% of the Market

During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.

May 31, 2023 | theglobeandmail.com

Closing Bell: Knight Therapeutics Inc down on Wednesday (GUD)

May 26, 2023 | finance.yahoo.com

Samira Sakhia Bought 12% More Shares In Knight Therapeutics

May 26, 2023 | finance.yahoo.com

Samira Sakhia Bought 12% More Shares In Knight Therapeutics \

May 23, 2023 | finance.yahoo.com

Shareholders in Knight Therapeutics (TSE:GUD) are in the red if they invested five years ago

May 8, 2023 | theglobeandmail.com

Closing Bell: Knight Therapeutics Inc down on Monday (GUD)

June 10, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

May 4, 2023 | finance.yahoo.com

Notice of Knight Therapeutics' First Quarter 2023 Results Conference Call

April 28, 2023 | theglobeandmail.com

Closing Bell: Knight Therapeutics Inc down on Friday (GUD)

April 18, 2023 | finance.yahoo.com

Knight to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

April 10, 2023 | theglobeandmail.com

Closing Bell: Knight Therapeutics Inc up on Monday (GUD)

March 28, 2023 | americanbankingnews.com

Knight Therapeutics (TSE:GUD) Downgraded by National Bank Financial to "Sector Perform Market Weight"

March 27, 2023 | americanbankingnews.com

National Bankshares Trims Knight Therapeutics (TSE:GUD) Target Price to C$6.00

March 26, 2023 | americanbankingnews.com

Knight Therapeutics (TSE:GUD) Price Target Cut to C$6.50

March 25, 2023 | marketwatch.com

Knight Therapeutics Inc. ranks on The Globe and Mail's fourth-annual Women Lead Here benchmark of executive gender diversity

March 23, 2023 | finance.yahoo.com

Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results

March 22, 2023 | americanbankingnews.com

Knight Therapeutics (TSE:GUD) Hits New 52-Week Low at $4.92

February 28, 2023 | benzinga.com

Knight Therapeutics Stock (OTC:KHTRF), Quotes and News Summary

January 27, 2023 | nypost.com

Spielberg: ‘Dark Knight’ should’ve been Oscars’ first Best Picture blockbuster

January 18, 2023 | msn.com

Wayne Knight Claims Seinfeld 'Obliterated' His Film Career

November 8, 2022 | finance.yahoo.com

Bullish insiders bet CA$2.9m on Knight Therapeutics Inc. (TSE:GUD)

October 11, 2022 | finance.yahoo.com

Knight Therapeutics Inc. (TSE:GUD) most popular amongst individual investors who own 57%, insiders hold 20%

September 23, 2022 | finance.yahoo.com

Knight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing Companies

September 1, 2022 | reuters.com

Knight Therapeutics Inc

August 15, 2022 | finance.yahoo.com

Knight Therapeutics Assumes Commercial Activities and Re-Launches Exelon in Brazil

See More Headlines

GUD Price History

30 days | 90 days | 365 days | Advanced Chart

GUD Company Calendar

Last Earnings: 3/23/2023
Today: 6/10/2023
Next Earnings (Estimated): 8/10/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Industry: Drug Manufacturers—Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: TSE:GUD
CUSIP: N/A
CIK: N/A
Web: www.gud-knight.com
Phone: 514-484-4483
Fax: N/A
Employees: 698
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: C$5.97
High Stock Price Forecast: C$6.50
Low Stock Price Forecast: C$5.40
Forecasted Upside/Downside: +19.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): C($0.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: -1013.5
Net Income: C$-15,020,000.00
Net Margins: -4.81%
Pretax Margin: N/A
Return on Equity: -1.82%
Return on Assets: -0.68%

Debt

Debt-to-Equity Ratio: 10.09
Current Ratio: 2.98
Quick Ratio: 1.79

Sales & Book Value

Annual Sales: C$312.35 million
Price / Sales: 1.74
Cash Flow: C$1.29 per share
Price / Cash Flow: 3.85
Book Value: C$7.44 per share
Price / Book: 0.67

Miscellaneous

Outstanding Shares: 108,840,000
Free Float: N/A
Market Cap: C$542.02 million
Optionable: Not Optionable
Beta: 0.52

Key Executives

Mr. Jonathan Ross Goodman B.A. (Age 54)
BA, L.L.B., LLB, M.B.A., MBA, Exec. Chairman
Comp: $250.94k

Ms. Samira Sakhia BCom (Age 55)
CA, CPA, MBA, Pres, CEO & Director
Comp: $674.28k

Mr. Arvind Utchanah
Chief Financial Officer

Ms. Amal Khouri B.Sc.
M.B.A., Chief Bus. Officer

Mr. Jeff Martens
Global VP of Commercial

Mr. Stephani Saverio
VP of Bus. Devel.

Mr. Leopoldo Bosano
Vice-Pres of Manufacturing & Operations

Ms. Monica Percario
Global VP of Scientific Affairs

Ms. Susan Caroline Emblem
Global VP of HR

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

GUD Stock - Frequently Asked Questions

Should I buy or sell Knight Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GUD shares.
View GUD analyst ratings or view top-rated stocks.
What is Knight Therapeutics' stock price forecast for 2023?: 2 Wall Street analysts have issued 12 month price objectives for Knight Therapeutics' stock. Their GUD share price forecasts range from C$5.40 to C$6.50. On average, they expect the company's share price to reach C$5.97 in the next year. This suggests a possible upside of 19.8% from the stock's current price.
View analysts price targets for GUD or view top-rated stocks among Wall Street analysts.
How have GUD shares performed in 2023?: Knight Therapeutics' stock was trading at C$5.18 on January 1st, 2023. Since then, GUD shares have decreased by 3.9% and is now trading at C$4.98.
View the best growth stocks for 2023 here.
When is Knight Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our GUD earnings forecast.
How were Knight Therapeutics' earnings last quarter?: Knight Therapeutics Inc. (TSE:GUD) released its quarterly earnings results on Thursday, March, 23rd. The company reported $0.02 EPS for the quarter. The company earned $81.66 million during the quarter, compared to analysts' expectations of $62 million. Knight Therapeutics had a negative net margin of 4.81% and a negative trailing twelve-month return on equity of 1.82%.
What other stocks do shareholders of Knight Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Constellation Software (CSU), Bombardier, Inc. Class B (BBD.B), Brookfield Infrastructure Partners (BIP.UN), Enbridge (ENB), Spin Master (TOY), Alimentation Couche-Tard (ATD.B), Chemtrade Logistics Income Fund (CHE.UN), Canadian National Railway (CNR), Dollarama (DOL) and Extendicare (EXE).

What is Knight Therapeutics' stock symbol?: Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD."
How do I buy shares of Knight Therapeutics?: Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Knight Therapeutics' stock price today?: One share of GUD stock can currently be purchased for approximately C$4.98.
How much money does Knight Therapeutics make?: Knight Therapeutics (TSE:GUD) has a market capitalization of C$542.02 million and generates C$312.35 million in revenue each year. The company earns C$-15,020,000.00 in net income (profit) each year or C($0.14) on an earnings per share basis.
How many employees does Knight Therapeutics have?: The company employs 698 workers across the globe.
How can I contact Knight Therapeutics?: Knight Therapeutics' mailing address is 3400 de Maisonneuve Boulevard West, Suite 1055, Montreal, QC H3Z 3B8, Canada. The official website for the company is www.gud-knight.com. The company can be reached via phone at 514-484-4483.

This page (TSE:GUD) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial